Introduction {#sec1_1}
============

The correlation of end-stage renal disease (ESRD) with infertility has been highlighted in recent years \[[@B1]\], as ovulation in an altered hormonal milieu can cause infertility \[[@B2]\]. Menstruation is associated with ovulation, and one of the cardinal signs of anovulation is the irregularity or absence of a menstrual period \[[@B3]\]. Thus, there is a close correlation between infertility and menstrual disturbances in premenopausal women. Menstrual disturbances, especially secondary amenorrhea, are commonly seen among premenopausal women with ESRD \[[@B4]\]. It is postulated that elevated serum prolactin (PRL) levels may partly contribute to the occurrence of menstrual disturbances \[[@B5]\]. The mechanisms for hyperprolactinemia in chronic renal failure are not well defined, but a possible cause could be an increased autonomous production rate of PRL; however, in ESRD patients, a decreased metabolic clearance rate might also play a role \[[@B6]\].

Factors other than sex hormone imbalances could also be responsible for menstrual disturbances since ovarian function is intact in ESRD patients, but other hormones, such as leptin, are abnormal \[[@B7],[@B8]\]. In general, the serum leptin level is significantly elevated in patients with kidney failure compared with controls matched for age and body mass index \[[@B9]\]. Leptin appears to be one factor influencing the maturation of the gonadotropin-releasing hormone pulse generator.

Some hormonal disturbances can be corrected by normalization of the serum PRL level through improving renal replacement therapy such as nocturnal hemodialysis (NHD) or renal transplantation (RT) \[[@B10],[@B11]\]. Despite successful RT, in previous studies \[[@B12],[@B13]\], menstrual disturbances were commonly seen in premenopausal women with ESRD. Thus, the role and effects of RT on menstrual cycle remodeling in premenopausal women with ESRD remain controversial. Hence, in this cross-sectional study, we aimed to evaluate the prevalence of menstrual disturbances and sex hormonal status in premenopausal women receiving different types of renal replacement therapy at our hospital.

Patients and Methods {#sec1_2}
====================

Ethical permission was obtained from the Scientific Committee at the Yantaishan Hospital and the Yantai Hospital of Traditional Chinese Medicine. Written informed consent was obtained from all the patients before enrollment. Exclusion criteria were genital tract infection, clotting disturbances, a history of menstrual disturbances before chronic kidney disease and use of sex hormones in the prior 2 years. A total of 184 patients were initially enrolled and divided equally into four groups (each n = 46) based on the type of renal replacement therapy: conventional hemodialysis (CHD), continuous ambulatory peritoneal dialysis (CAPD), NHD and RT. Patients were 14--44 years old and had received more than 6 months of renal replacement therapy. In the RT group, the transplanted organs were obtained from executed prisoners (n = 34) or cadaveric donors (n = 12).

Nineteen patients did not complete the final analysis because of the following reasons: not providing the characteristics of the menstrual cycle (6 patients), switching to another renal replacement therapy (8 patients) or missing information about the serum hormonal status (5 patients). The 19 excluded patients were from the following groups: CAPD, 3; NHD, 6, and RT, 10. Hence, 165 of the initial 184 patients completed the study. Menstrual patterns in the 165 patients were recorded in detail. Menstrual cycles were classiﬁed into polymenorrhea (\<22 days), normal (22--35 days) and oligomenorrhea (\>35 days). Absence of menses for at least 6 months was diagnosed as secondary amenorrhea.

From menstruating women, blood samples were collected once during the 1st month after admission after overnight fasting for the measurement of serum sex hormonal status, including PRL, follicle-stimulating hormone (FSH), luteinizing hormone (LH), progesterone and testosterone. Blood samples were prepared by storing blood at 4°C for 1 h, and the resulting coagulated blood cells were then separated from the serum by centrifugation at 4,000 *g* for 20 min. The serum samples were transferred to new microtubes and stored at −80°C until analysis. Blood samples for the detection of PRL, FSH and LH were collected in the morning on days 3--5 of the cycle, and the hormones were measured using chemiluminescence. Blood samples for the detection of progesterone and testosterone were collected 4--6 days before anticipated menses and hormone levels were also measured using chemiluminescence. In nonmenstruating women, the levels of serum sex hormones were measured once on the same day.

Prescription of Dialysis and RT {#sec2_1}
-------------------------------

The dialysis prescriptions were as follows: the CHD group: 4 h/session and 3 sessions/week; the CAPD group: 3 exchanges/day; the NHD group: 6--8 h/session and 4--5 sessions/week. The RT group underwent a full functioning RT (serum creatinine 0.8--1.3 mg/dl and glomerular filtration rate \>90 ml/min), and all patients were on a stable corticosteroid immunosuppressive regimen for at least 6 months.

Demographic and Clinical Data at Baseline {#sec2_2}
-----------------------------------------

Demographic data including menstrual patterns, the duration of primary kidney disease as well as the type, number and duration of medications for kidney disease were collected by questionnaire completed by the patients. Age, body mass index, primary kidney disease leading to renal failure, renal replacement modality, duration of renal replacement (months) and laboratory data including hemoglobin and residual kidney function (assessment of urinary volume) were obtained from medical records. All patients were given immunosuppressive therapy if necessary according to their previous condition. The use of corticosteroids and immunosuppressive drugs is summarized in table [1](#T1){ref-type="table"}. A questionnaire was administered for the menstrual pattern.

Statistical Analysis {#sec2_3}
--------------------

All values are expressed as means ± SD or percentages as appropriate. A two-tailed p \< 0.05 was considered significant. Differences in proportions were tested using Pearson\'s χ^2^ test; differences in means were tested using one-way analysis of variance or the Mann-Whitney test as appropriate. All statistical analyses were evaluated using SPSS 18.00 (IBM Corporation, Armonk, N.Y., USA).

Results {#sec1_3}
=======

Patients\' Characteristics {#sec2_4}
--------------------------

The demographic and socioeconomic characteristics of the total population are summarized in table [1](#T1){ref-type="table"}. The mean age of the patients was 34.7 ± 5.3 years. There were no significant differences in sociodemographic and clinical data among the four groups.

Prevalence of Menstrual Disturbances in the Different Groups {#sec2_5}
------------------------------------------------------------

The overall prevalence of menstrual disturbances was 64.2s%, and for each treatment modality, it was 76.1, 72.1, 55.00 and 50.0s% for the CHD, CAPD, NHD and RT groups, respectively. The prevalence of menstrual disturbances was highest in the CHD group and lowest in the RT group (p \< 0.05). The top two menstrual disturbances were secondary amenorrhea and polymenorrhea (table [2](#T2){ref-type="table"}), which accounted for more than 85s% of all menstrual disturbances in the four groups. Oligomenorrhea was the least frequent disturbance among the four groups.

Hormonal Status in the Different Groups {#sec2_6}
---------------------------------------

The hormonal status of menstruating and nonmenstruating patients in the four groups is shown in table [3](#T3){ref-type="table"}. Serum PRL levels were significantly lower in the NHD (p \< 0.01) and RT (p \< 0.01) groups compared to the CHD group for both menstruating and nonmenstruating patients (p \< 0.05). Among the menstruating patients, there was no significant difference in serum FSH, LH or testosterone levels between the four groups (p \> 0.05). However, serum progesterone levels were significantly higher in the NHD (p \< 0.01) and RT (p \< 0.01) groups than in the CHD group. Moreover, sex hormonal status (including FSH, LH and testosterone) was close to normal in the NHD and RT groups, although the mean remained slightly above or below the normal range. No difference was evident in the serum progesterone levels in the nonmenstruating patients among the four groups (p \> 0.05).

Discussion {#sec1_4}
==========

The overall prevalence of menstrual disturbances in premenopausal women with ESRD was 64.2s%, which was lower than the 75.0s% reported in previous studies \[[@B14],[@B15]\] which investigated only CHD. The difference could be attributed to the fact that we included NHD and RT separately besides CHD, which had prevalences of 55.0 and 50.0s%, respectively, and, hence, both were more effective than CHD in lowering the prevalence of menstrual disturbances because the corresponding prevalence of CHD was 76.1s%. In this study, the prevalence rates of menstrual disturbances of 76.1s% (CHD) and 72.1s% (CAPD) did not support the theory that CAPD outperforms CHD in preserving residual renal function and promoting PRL excretion as previously stated \[[@B16]\], and thus could benefit the menstrual cycles in premenopausal patients with ESRD. A possible explanation could be that CAPD is not very effective in the above two areas (preserving residual renal function and promoting PRL excretion) \[[@B17]\].

Menstrual disturbances were still common even after successful RT (50s%), which was in agreement with a previous study \[[@B18]\]. It has been postulated that the hypothalamic-pituitary-gonadal axis is permanently altered following ESRD, although the normalization of hormonal status could be influenced by immunosuppressive treatments and other medications, such as corticosteroids and β-blockers \[[@B19]\]. As previously reported, the use of immunosuppressants (e.g. cyclophosphamide) or tripterygium contributes to premature ovarian failure \[[@B20],[@B21]\]. Moreover, systemic lupus erythematosus, a common cause of ESRD, can influence the menstrual pattern \[[@B22]\]. Depressive disorder was seen among ESRD patients \[[@B23]\], and depression can have a negative effect on the menstrual cycle \[[@B24]\]. A majority of ESRD patients suffer from one or more chronic illnesses, such as hypertension, anemia and diabetes mellitus. Moreover, chronic disorders, especially diabetes mellitus, can cause menstrual disturbances through alterations in the hypothalamic-pituitary-gonadal axis \[[@B25]\]. All of these factors might contribute to the menstrual disturbances in premenopausal women with ESRD. However, we did not study these potentially relevant factors influencing menstrual disturbances.

In our study, more than half of the menstrual disturbances were due to secondary amenorrhea, which is within the 24--63s% reported in previous reviews \[[@B26],[@B27]\]. Hyperprolactinemia might also contribute to this discrepancy. Serum PRL levels were significantly more normal in the NHD and RT groups than in the other two groups regarding both menstruating and nonmenstruating patients (p \< 0.05) in our study. One reason for this might be that NHD could result in a decreased peak and flattened curve of secreted PRL \[[@B28],[@B29]\]. Also, the total dialysis time per week was significantly longer in the NHD group than in the CHD group (35.3 ± 4.7 vs. 11.1 ± 1.9 h/week, respectively), which improved serum PRL removal. RT was more advantageous than the other three therapies because (1) RT restores residual renal function, since the kidney can remove 25s% of serum PRL from the circulation \[[@B30]\], and (2) it restores menses and fertility, as indicated by the normalization of the hormonal serum profile \[[@B18]\]. Meanwhile, a circadian rhythm difference in serum PRL levels is known to be involved in the differences across studies. We also observed a more significant improvement in the status of other hormones with an elevation of the circulating progesterone level in the NHD (p \< 0.01) and RT (p \< 0.01) groups compared with the CHD group among menstruating patients based on decreased levels of uremic toxins or restoration of residual renal function.

Conclusion {#sec1_5}
==========

In this study, successful transplantation or NHD improved the symptoms of menstrual disturbances. However, further studies are necessary to confirm our findings in ESRD patients.

Disclosure Statement {#sec1_6}
====================

The authors have no conflict of interest.

###### 

Sociodemographic and clinical data of the patients

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                       CHD group\          CAPD group\       NHD group\          RT group\           p value
                                                                                       (n = 46)            (n = 43)          (n = 40)            (n = 36)            
  ------------------------------------------------------------------------------------ ------------------- ----------------- ------------------- ------------------- ---------
  Age, years                                                                           34.6 ± 5.4          34.5 ± 5.8        35.2 ± 5.1          34.5 ± 4.8          0.21

  Primary kidney disease, s%                                                                                                                                         1.0

   Glomerulonephritis                                                                  58.7                60.5              62.5                61.1                

   Pyelonephritis                                                                      4.3                 4.6               5.0                 5.6                 

   Hypertensive nephrosclerosis                                                        8.7                 9.3               10.0                8.3                 

   Diabetic nephropathy                                                                15.3                14.0              12.5                13.9                

   Polycystic kidney disease                                                           8.7                 4.6               2.5                 5.5                 

   Lupus nephritis                                                                     4.3                 4.6               7.5                 2.8                 

   Other                                                                               0                   2.4               0                   2.8                 

  Duration of renal disease, years                                                     4.7 ± 1.3           4.5 ± 1.5         4.8 ± 2.2           4.7 ± 1.6           0.17

  Body mass index                                                                      23.5 ± 7.5          23.7 ± 6.3        24.1 ± 4.9          23.8 ± 5.2          0.63

  Hemoglobin, g/l                                                                      11.7 ± 2.8          12.1 ± 8.9        12.5 ± 4.5          11.6 ± 2.4          0.11

  rHuEPO, IU/week                                                                      8,417.2 ± 1,133.8   8,222.5 ± 948.1   8,208.9 ± 1,247.1   8,112.0 ± 1,344.9   0.53

                                                                                                                                                                     

  Type of medications for kidney disease, s%                                                                                                                         

   Glucocorticoids                                                                     69.6                72.1              77.5                75.0                0.86

   Immunosuppressants                                                                  41.3                41.9              45.0                44.4                0.98

   Tripterygium glycosides                                                             17.4                16.3              17.5                19.4                0.99

  Number of medications for kidney disease^1^, s%                                                                                                                    0.98

   \<2 medications                                                                     28.3                27.9              25.0                25.0                

   \>2 medications                                                                     71.7                72.1              75.0                75.0                

  Duration of medication use for kidney disease[^1^](#T1F1){ref-type="table-fn"}, s%                                                                                 0.99

   \<2 years                                                                           6.5                 7.0               7.5                 8.3                 

   ≥2 years                                                                            93.5                93.0              92.5                91.7                

                                                                                                                                                                     

  Dialysis duration, months                                                            52.2 ± 7.8          48.5 ± 11.3       51.9 ± 10.1         49.8 ± 10.2         0.49

  Dialysis sessions, n/week                                                            3.2 ± 0.3                             5.5 ± 0.5                               0.03

  Duration of dialysis sessions, h                                                     4.3 ± 0.2                             7.4 ± 1.6                               0.02

  Total dialysis time, h/week                                                          11.1 ± 1.9                            35.3 ± 4.7                              0.003

  Weight after dialysis, kg                                                            67.7 ± 8.3          66.9 ± 10.1       65.6 ± 5.2                              0.42

  Residual kidney function, s%                                                                                                                                       

   \<100 ml/24 h                                                                       87.0                67.4              77.5                0                   0.001

   ≥100 ml/24 h                                                                        13.0                32.6              22.5                100                 

  Weekly Kt/V                                                                          3.24 ± 1.26         2.95 ± 1.25       4.27 ± 0.83                             0.04
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Medications associated with ovarian function include glucocorticoids, immunosuppressants and tripterygium glycosides.

###### 

Prevalence rates of various menstrual disturbances according to the different types of renal replacement therapy

  --------------------------------------------------------------------
                   CHD group\   CAPD group\   NHD group\   RT group\
                   (n = 35)     (n = 31)      (n = 22)     (n = 18)
  ---------------- ------------ ------------- ------------ -----------
  Amenorrhea       60s%         58.1s%        54.5s%       61.1s%

  Polymenorrhea    22.9s%       25.8s%        27.3s%       38.9s%

  Oligomenorrhea   17.1s%       16.1s%        18.2s%       0s%
  --------------------------------------------------------------------

###### 

Hormonal status in menstruating and nonmenstruating patients among the different groups

  Characteristics               CHD group      CAPD group     NHD group                                        RT group
  ----------------------------- -------------- -------------- ------------------------------------------------ -----------------------------------------------
  Menstruating patients, n      11             12             18                                               18
   Serum PRL, ng/ml             55.2 ± 10.8    46.4 ± 8.3     25.1 ± 10.9[\*\*](#T3F2){ref-type="table-fn"}    13.4 ± 5.1[\*\*](#T3F2){ref-type="table-fn"}
   Serum FSH, μIU/ml            21.2 ± 10.4    18.4 ± 6.6     18.2 ± 7.3                                       17.7 ± 6.3
   Serum LH, μIU/ml             31.1 ± 17.4    26.5 ± 10.5    26.9 ± 10.1                                      25.2 ± 7.3
   Serum progesterone, nmol/l   17.7 ± 7.3     18.4 ± 6.6     25.7 ± 8.3[\*\*](#T3F2){ref-type="table-fn"}     30.1 ± 5.9[\*\*](#T3F2){ref-type="table-fn"}
   Serum testosterone, ng/ml    0.48 ± 0.25    0.49 ± 0.13    0.44 ± 0.16                                      0.53 ± 0.21
                                                                                                               
  Nonmenstruating patients, n   35             31             22                                               18
   Serum PRL, ng/ml             218.4 ± 39.1   185.6 ± 38.4   135.2 ± 45.8[\*\*](#T3F2){ref-type="table-fn"}   93.6 ± 11.4[\*\*](#T3F2){ref-type="table-fn"}
   Serum FSH, μIU/ml            135.8 ± 56.4   122.3 ± 31.8   107.6 ± 14.4[\*](#T3F1){ref-type="table-fn"}     75.9 ± 22.1[\*\*](#T3F2){ref-type="table-fn"}
   Serum LH, μIU/ml             65.8 ± 29.2    68.1 ± 22.9    48.1 ± 13.9[\*](#T3F1){ref-type="table-fn"}      36.3 ± 23.7[\*\*](#T3F2){ref-type="table-fn"}
   Serum progesterone, nmol/l   9.1 ± 4.4      9.5 ± 5.2      9.7 ± 4.3                                        10.2 ± 6.8
   Serum testosterone, ng/ml    0.37 ± 0.23    0.39 ± 0.15    0.56 ± 0.17[\*](#T3F1){ref-type="table-fn"}      0.71 ± 0.29[\*\*](#T3F2){ref-type="table-fn"}

p \< 0.05

p \< 0.01, vs. the CHD group.
